These data suggested a crosstalk between IFN signaling and FGF signaling in RAG cells, and that FGF inhibition by lenvatinib can maintain the expression level of B2M and PD-L1 on cancer cells by prolonging IFN-γ signaling. This evidence concerns the gene CD274 and cancer.